A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys
Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
It is hoped that mobocertinib will eventually help people with cancer with severely reduced
kidney function. The main aim of this study is to learn about the levels of mobocertinib in
the blood and urine of participants with severely reduced kidney function and participants
with healthy kidneys. These participants do not have cancer. The information from this study
will be used to work out the best dose of mobocertinib for people with cancer with severely
reduced kidney function in the future.
At the first visit, the study doctor will check who can take part. Participants who can take
part will be placed into 1 of 2 treatment groups. Participants with severely reduced kidney
function will be in 1 group. Participants with healthy kidneys will be in the other group.
Participants in both groups will receive the same treatment and the group results will be
compared.
Participants from both groups will take 1 capsule of mobocertinib. They will stay in the
clinic for 10 days so the study doctors can check the amount of mobocertinib in the blood and
urine of these participants over time. The study doctors will also check if the participants
have any side effects from this treatment.
The clinic will call the participants 30 days after they took mobocertinib to check if they
have any more side effects from their treatment.